Know Cancer

or
forgot password

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Anthracycline- And Taxane-Resistant Metastatic Breast Cancer


Phase 2
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Anthracycline- And Taxane-Resistant Metastatic Breast Cancer


OBJECTIVES:

Primary

- Determine the antitumor efficacy of SU011248, in terms of objective response rate
(confirmed complete or partial response), in women with anthracycline- or
taxane-resistant metastatic breast cancer.

Secondary

- Determine the duration of tumor control and 1-year survival rate of patients treated
with this drug.

- Determine the safety of this drug in these patients.

- Correlate plasma concentrations of this drug with efficacy and safety parameters in
these patients.

- Correlate potential cancer biomarkers with cancer- and treatment-related outcomes in
patients treated with this drug.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral SU011248 once daily on days 1-28. Courses repeat every 42 days for up
to 1 year in the absence of disease progression or unacceptable toxicity. Patients may then
continue to receive SU011248 on this protocol or a separate continuation protocol.

Patients are followed at 1 month and then every 2 months for 1 year.

PROJECTED ACCRUAL: A total of 38-63 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed breast adenocarcinoma

- Metastatic disease

- Not amenable to surgery, radiotherapy, or combined modality therapy with curative
intent

- Anthracycline-resistant OR taxane-resistant disease, defined as relapse or disease
progression during treatment or within 12 months after completion of an anthracycline
or a taxane

- Received both a prior anthracycline-based and a prior taxane-based chemotherapy
regimen either concurrently or sequentially in the adjuvant and/or advanced
disease treatment setting

- Measurable disease, defined as ≥ 1 unidimensional lesion ≥ 20 mm by conventional
radiographic techniques or MRI OR ≥ 10-16 mm by spiral CT scan (depending on
interval)

- Positron emission tomography or ultrasound may not be substituted for MRI or CT
scan

- The following are not considered measurable disease:

- Bone lesions

- Ascites

- Peritoneal carcinomatosis

- Miliary lesions

- Pleural or pericardial effusions

- Lymphangitis of the skin or lung

- Cystic lesions

- Irradiated lesions

- Disease documented by indirect evidence only (e.g., by laboratory tests
such as alkaline phosphatase)

- No known brain metastases or carcinomatous meningitis

- No new evidence of brain or leptomeningeal disease on screening CT scan or MRI

- No spinal cord compression

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age

- 18 and over

Sex

- Female

Menopausal status

- Not specified

Performance status

- ECOG 0-1

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9.0 g/dL

Hepatic

- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver
metastases)

- Bilirubin ≤ 1.5 times ULN

- PT and PTT ≤ 1.5 times ULN

- Albumin ≥ 3.0 g/dL

Renal

- Creatinine ≤ 1.5 times ULN

Cardiovascular

- LVEF ≥ 10% above lower limit of normal by MUGA

- None of the following within the past year:

- Myocardial infarction

- Severe or unstable angina

- Symptomatic congestive heart failure

- Cerebrovascular accident or transient ischemic attack

- Deep vein thrombosis

- Other thromboembolic event

- No ongoing cardiac dysrhythmias ≥ grade 2

- No atrial fibrillation of any grade

- No prolongation of the QTc interval to > 470 msec

Pulmonary

- No pulmonary embolism within the past year

Other

- Adrenocorticotrophic hormone-stimulation test normal

- Amylase and lipase normal

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or carcinoma in situ of the cervix

- No other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that would preclude study participation

- No known HIV infection or AIDS-related illness

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 30 days after study
treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Chemotherapy

- Recovered from prior cytokine therapy

- Prior immunotherapy in the adjuvant and/or advanced/metastatic disease setting
allowed

- At least 3 weeks since prior immunotherapy

- No other concurrent vascular endothelial growth factor inhibitors or angiogenic
inhibitors

- No concurrent biologic response modifiers

- No concurrent immunotherapy

Chemotherapy

- See Disease Characteristics

- No prior non-anthracycline non-taxane chemotherapy agent in the advanced/metastatic
disease setting

- No prior chemoembolization to only site of measurable disease

- At least 3 weeks since prior chemotherapy

- No prior high-dose-chemotherapy requiring hematopoietic stem cell rescue

- No concurrent chemotherapy

Endocrine therapy

- Prior hormonal therapy in the adjuvant and/or advanced/metastatic disease setting
allowed

- At least 3 weeks since prior hormonal therapy

- No concurrent hormonal therapy

Radiotherapy

- No prior radiotherapy to only site of measurable disease

- At least 3 weeks since prior radiotherapy and recovered

- No prior radiotherapy to > 25% of the bone marrow

- Concurrent palliative radiotherapy allowed provided measurable lesions are outside
the irradiated field

Surgery

- Recovered from prior surgery

- No prior surgery to only site of measurable disease

- More than 1 year since prior coronary or peripheral artery bypass graft

- No concurrent surgery to only site of measurable disease

Other

- No prior cryotherapy to only site of measurable disease

- Concurrent bisphosphonate therapy allowed for metastatic bone disease provided
treatment was initiated at least 3 months before study entry

- No other concurrent tyrosine kinase inhibitors

- No concurrent treatment on another clinical trial

- No concurrent drugs with dysrhythmic potential (e.g., terfenadine, quinidine,
procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, or
indapamide)

- No concurrent ketoconazole

- No other concurrent approved or investigational anticancer therapy

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Mark D. Pegram, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000393973

NCT ID:

NCT00095615

Start Date:

September 2004

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage IV breast cancer
  • recurrent breast cancer
  • Breast Neoplasms

Name

Location

Jonsson Comprehensive Cancer Center at UCLALos Angeles, California  90095-1781